Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H20BrN5O2.ClH |
| Molecular Weight | 502.791 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=C(NC(=O)NC2=CC=CC3=C2C=CN3CC4=CC=NC(N)=C4)C=C(Br)C=C1
InChI
InChIKey=WWUKDILHPZKGIL-UHFFFAOYSA-N
InChI=1S/C22H20BrN5O2.ClH/c1-30-20-6-5-15(23)12-18(20)27-22(29)26-17-3-2-4-19-16(17)8-10-28(19)13-14-7-9-25-21(24)11-14;/h2-12H,13H2,1H3,(H2,24,25)(H2,26,27,29);1H
CGI-1842 (also known as JI-101) is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor β (PDGFR-β), and ephrin type-B receptor 4 that has been used in trials studying the treatment of Cancer, Colon Cancer, Neuroendocrine, Ovarian Cancer, and Advanced Solid Tumors. By targeting multiple angiogenesis signaling pathways in tumor vessel beds, CGI-1842 has the potential to inhibit multiple stages of tumor angiogenesis and thus enhance anti-tumor efficacy. In preclinical models, CGI-1842 induced concentration-dependent blocking of both EphB4- and VEGF-stimulated signaling pathways and has shown excellent antitumor activity. CGI-1842 is well tolerated in cancer patients and has shown impressive activity in Phase I clinical trials.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
44472553
Created by
admin on Mon Mar 31 18:48:42 GMT 2025 , Edited by admin on Mon Mar 31 18:48:42 GMT 2025
|
PRIMARY | |||
|
1441001-34-8
Created by
admin on Mon Mar 31 18:48:42 GMT 2025 , Edited by admin on Mon Mar 31 18:48:42 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
7FM1I0S6F4
Created by
admin on Mon Mar 31 18:48:42 GMT 2025 , Edited by admin on Mon Mar 31 18:48:42 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
